Cite
HARVARD Citation
Mahalingam, D. et al. (n.d.). 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. Journal for immunotherapy of cancer. p. A228. [Online].